KinetoChem

What KinetoChem does

KinetoChem LLC is a US-based, privately held pharmaceutical manufacturer founded in 2016 and headquartered in Georgetown, Texas, that produces high-purity synthetic cannabinoid Active Pharmaceutical Ingredients (APIs) for pharmaceutical, biotechnology, and research customers. The company specializes in small-molecule synthesis and large-scale liquid chromatography purification to deliver neutral cannabinoids (e.g., CBD, THC, CBN, CBC, CBG and their variants), cannabinoid acids (e.g., CBDA, THCA, CBGA), alkyl homologs (CBD-C1 through CBD-C9), and enantiomers/stereoisomers, with materials supplied from milligram quantities for early-phase R&D through kilogram-scale commercial production. Its operations are anchored by three DEA Schedule I licenses (Bulk Manufacturing, Export, and Analytical) and cGMP-aligned processes, and the company has supported an FDA Drug Master File for synthetic Cannabidiol.

KinetoChem sells DEA-licensed, cGMP-grade synthetic cannabinoid APIs through a direct enterprise sales motion targeting pharmaceutical companies developing cannabinoid-based drug products (primary segment) and research institutions conducting pre-clinical and analytical studies (secondary segment). Pricing is not publicly disclosed and is provided on a quote basis, consistent with a project-driven, B2B contract structure rather than a transactional catalog. The company also offers custom synthesis services for compounds outside its standard inventory, expanding the addressable API market on a request basis. The firm is founder-owned and operated, with Founder & CSO Everett McKinley overseeing synthesis, purification, and analytical development, and with operations underpinned by a US phone number and email-based inquiry channel plus a LinkedIn presence and a downloadable technical whitepaper as its principal marketing assets.

The company maintains a global reach in principle through its DEA Schedule I Export license, although the publicly stated served market is the United States. KinetoChem faces the structural risk that its customer base is a small universe of DEA-licensed pharmaceutical and research buyers with long drug-development cycles, but it is differentiated by the scarcity of Schedule I bulk-manufacturing licenses, a founder with prior DMF authorship and cGMP facility-design experience, and an unusually broad synthetic cannabinoid catalog.

Name

KinetoChem

Legal name

KinetoChem LLC

Website

https://kinetochem.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

1–10 employees

Short description

KinetoChem LLC is a US-based, DEA-licensed manufacturer of high-purity synthetic cannabinoid APIs, supplying pharmaceutical companies and research institutions with cGMP-grade materials from milligram R&D quantities to kilogram commercial production.

Ownership category

akta.pro rank

Product category

Pharmaceutical API Manufacturing

NAICS

Medicinal and Botanical Manufacturing (325411), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)

akta.pro industry

PRIMARYHLAGAHAB

Small-Molecule API Commercial Manufacturing

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

SECONDARYHLAGAHAD

Controlled Substances / DEA-Scheduled API Manufacturing

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

SECONDARYHLAGAHAA

Small-Molecule API Process Development & Route Scouting

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

• Synthetic cannabinoid APIs
• Pharmaceutical API manufacturing
• DEA licensed manufacturing
• CGMP cannabinoid production
• Active pharmaceutical ingredients

Headquarters

HQ city

Georgetown

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Synthetic Cannabinoid API Sales: Sale of high purity synthetic cannabinoid Active Pharmaceutical Ingredients including CBD, THC, and minor cannabinoids at various quantities (milligram, gram, kilogram) for early phase R&D, pre-clinical, clinical trials, and commercial production.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

KinetoChem LLC is a US-based, DEA-licensed manufacturer of high-purity synthetic cannabinoid Active Pharmaceutical Ingredients (APIs) including CBD, THC, minor cannabinoids, cannabinoid acids, and stereoisomers. The company produces materials at scales from milligram quantities for early-phase R&D through kilogram-scale commercial production, serving pre-clinical, clinical, and commercial pharmaceutical drug development. Manufacturing processes meet FDA and cGMP guidelines, and the company offers custom synthesis for compounds outside its standard inventory.

Product overview

KinetoChem LLC is a US-based pharmaceutical manufacturer specializing in high-purity synthetic cannabinoid Active Pharmaceutical Ingredients (APIs). The company offers a comprehensive portfolio of synthetic cannabinoids spanning neutral cannabinoids (CBD, THC, CBN, CBC, CBG and their variants) and cannabinoid acids (CBDA, THCA, CBGA and related acids), including both natural forms and synthetic enantiomers/stereoisomers. KinetoChem provides materials across all scales—from milligram quantities for early-phase R&D through to kilogram-scale commercial production—with capabilities for pre-clinical studies, clinical trials, and commercial pharmaceutical applications. Their manufacturing processes adhere to FDA and cGMP guidelines, and they hold three DEA Schedule I licenses for Bulk Manufacturing, Export, and Analytical operations. The company also offers custom synthetic cannabinoid synthesis services for compounds not in their standard inventory.

Differentiator

Problem solved

Functional benefit

Products and services

• Cannabidiorcin (CBD-C1)

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators1 record

Recent moves6 records

Expansion highlights4 records

Regional players

• Bedrocan: Dutch producer of pharmaceutical-grade cannabis APIs supplied to multiple European countries under government contracts. Comparable to KinetoChem in pharmaceutical-grade cannabinoid supply, but focused on plant-derived rather than synthetic APIs and primarily serving European regulated markets.

Direct peers

• Aphios Pharma: US-based pharmaceutical company developing cannabinoid-based therapeutics with API manufacturing capability. Overlaps with KinetoChem in DEA-licensed synthetic cannabinoid API production for clinical-stage cannabinoid drugs.
• ElSohly Laboratories: DEA-licensed manufacturer of cannabis-derived and synthetic cannabinoid drug substances for research and FDA-regulated pharmaceutical use, and a long-standing NIDA supplier. Directly comparable to KinetoChem as a US DEA Schedule I cannabinoid API manufacturer serving pharma clients.
• Echo Pharmaceuticals: Netherlands-based developer and manufacturer of pharmaceutical-grade cannabinoid APIs and finished dosage forms for European markets. Comparable to KinetoChem as a cGMP-grade synthetic cannabinoid API supplier targeting regulated pharmaceutical customers.

Broad incumbents

• Cerilliant (Sigma-Aldrich / Merck): Cerilliant, now part of Merck KGaA's life science tools business, is the historical reference-standard and synthetic cannabinoid/API manufacturer that KinetoChem's founder trained at (Radian Corporation, which became Cerilliant). It is the closest established comparable in synthetic cannabinoid chemistry at scale.
• Jazz Pharmaceuticals: Owner of Epidiolex (FDA-approved plant-derived CBD), the dominant commercial cannabinoid pharmaceutical franchise. Represents the demand-side analog to KinetoChem's supply position and a potential acquirer/customer of synthetic cannabinoid APIs for follow-on programs.
• Tilray Brands (Pharma / GMP division): Large cannabis operator with a GMP pharmaceutical division supplying cannabinoid APIs and finished products to research and pharma customers. A broader incumbent that competes for the same pharmaceutical-grade cannabinoid API demand.

Emerging players

• Ginkgo Bioworks: Synthetic biology platform that has publicly pursued fermentation-based cannabinoid production. A potential future competitor or partner to KinetoChem as synthetic biology routes to cannabinoids (especially minor cannabinoids) become commercially viable.
• PureForm CBD: US-based manufacturer of synthetic CBD APIs marketed as ultra-purity alternatives to plant-derived CBD. Directly comparable to KinetoChem as a synthetic cannabinoid API supplier targeting regulated pharmaceutical and consumer health markets.
• Indigo Agriculture (Indigo Pharma / Cannabinoid programs): Has worked on cannabinoid biosynthesis via engineered microbes; an adjacent emerging route to pharmaceutical-grade cannabinoid APIs that could compete with or complement KinetoChem's small-molecule synthesis approach.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/kinetochem

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about KinetoChem